These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24316634)

  • 1. Burning bright.
    Huggett B
    Nat Biotechnol; 2013 Dec; 31(12):1068-71. PubMed ID: 24316634
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 5. Divining the path to a successful European exit.
    Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
    Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech's wellspring-a survey of the health of the private sector in 2015.
    Huggett B
    Nat Biotechnol; 2016 Jun; 34(6):608-15. PubMed ID: 27281417
    [No Abstract]   [Full Text] [Related]  

  • 9. Enthusiasm cools in Q2.
    Lawrence S
    Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 11. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 12. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 13. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 14. Crystal gazing: biotech's financial outlook: the investment banker's view.
    Strupp DJ
    Nat Biotechnol; 2006 Mar; 24(3):263-4. PubMed ID: 16525375
    [No Abstract]   [Full Text] [Related]  

  • 15. Whither agbiotechnology?
    Val Giddings L
    Nat Biotechnol; 2006 Mar; 24(3):274-6. PubMed ID: 16525385
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 17. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 18. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 19. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 20. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.